Articles On Amplia Therapeutics (ASX:ATX)

Amplia Therapeutics (ASX: ATX) is a step closer to phase 2 clinical trials in pancreatic cancer and lung fibrosis after completing a manufacturing run of its lead focal adhesion kinase (FAK) inhibitor drug AMP945. The company’s contractor h...

Amplia Therapeutics (ATX) completes manufacture of its clinical-stage drug candidate ahead of planned trials A two-kilogram batch of the company’s AMP945 will be used in toxicology studies and phase two clinical trials in pancreatic cancer...

The batch was produced on time and within budget and represents a big step up from the 1-kilogram batch that’s been manufactured under GMP conditions previously.

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

“Our priorities for 2022 are clear – our goal will be to build on the solid foundations of the last 12 months and maintain this momentum as we move towards two phase-two trials in the new year,” says CEO.

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

The cash injection will fund the first stage of phase two clinical trials for AMP945, as well as manufacturing and further pre-clinical studies and additional working capital.

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has been granted a $2.1 million funding facility to accelerate work on its second focal adhesion kinase (FAK) inhibitor drug AMP886 for treating cancers and fibrotic disease. The company...

Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development (R&D) cash flow loan The $2.1 million will be awarded in two tranches: $1.3m in December this year and $0.8 million in the quarter ending March 31, 2022...

Amplia has designed a Phase 2 clinical trial of AMP945 in pancreatic cancer patients and plans to initiate patient recruitment at Australian sites in the first quarter of calendar 2022.

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

The company is optimistic about the results of its Phase 1 clinical trial with results supporting further development of AMP945 as a treatment for cancer and fibrosis.

Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) has received new data from a recent Phase 1 clinical trial which demonstrates the ability of lead drug AMP945 to inhibit focal adhesion kinase (FAK) in healthy human volunteer...

Amplia targets human trials for pancreatic cancer drug Noxopharm subsidiary enters licence agreement with Hudson Insitiute of Medical Research $7.2 million placement and $2 million SPP launched by Pharmaxis to support next phase of clinica...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The data will be used to further refine the doses of AMP945 to be used in a Phase 2 clinical trial in patients with pancreatic cancer and will provide guidance for the Phase 2 trial in pulmonary fibrosis planned for the second half of 2022.

The capital raise consists of a placement to institutional and sophisticated investors to raise $5.4 million and a one-for-four fully underwritten pro-rata non-renounceable entitlement offer to raise $7 million.

Proceeds from the placement and entitlement offer will be used to fund the first stage of a Phase 2 clinical trial for AMP945, manufacturing and further pre-clinical studies.

The ASX had a positive finish to the week taking its weekly return to 1.8%. Today the ASX 200 closed at 7,457 points, 0.39% higher than yeterday. Tech was heavily sold off, shedding 1.64% but almost all other sectors were in the green with...

The ASX rose 0.48% today to reach its highest point in the week. While energy lost 2% most other sectors were in the green with tech and financials gaining over 1%. Today’s gains came despite the Federal Reserve unveiling a tapering of stim...

Pharmaceutical company Amplia Therapeutics (ATX) enters into a trading halt as it plans an upcoming capital raise It is not known how much the company is aiming to raise or where the funds will be spent Under the halt, company shares will...

The company has also entered a trading halt as it undertakes a capital-raising process. The halt is in place until Monday, November 8, or when an announcement is released to the market.

Amplia Therapeutics is raising $12.4 million to fund human clinical trials and drug manufacturing for its drug candidate designed to slow cancer progression.

Amplia Therapeutics (ASX: ATX) has appointed experienced spearhead of pancreatic cancer treatments Dr José Iglesias as clinical advisor to assist with development of its cancer and fibroid drugs. The company pointed out that Dr Iglesias was...

José Iglesias MD will join the ATX team as a clinical advisor, providing more than 30 years of experience in the pharmaceutical industry.

Many successful investors in healthcare have made money by patiently backing companies that are quietly and strategically trying to solve big problems, like Australian biotech company Amplia Therapeutics (Amplia, ASX:ATX).

Clinical development company Amplia Therapeutics (ASX: ATX) has received a research and development tax incentive refund from the federal government for expenditure related to advancing its focal adhesion kinase (FAK) inhibitors for cancer...

The trial was completed during the first half of 2021 and leads into the company’s planned Phase 2 clinical trial in pancreatic cancer patients.

George will replace Jeff Carter, who is stepping down from the role after being the company’s CFO for more than eight years. 

New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned Phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a focal adhesion kinase (FAK) inhibitor prio...

FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus on pancreatic and ovarian cancer.

Amplia Therapeutics (ASX:ATX), which is developing new drugs for the treatment of cancer and fibrosis, has announced the publication of a paper from the Garvan Institute of Medical Research.

Both Amplia and Patrys have flagship drugs in development that take unique approaches to tackling cancers.

The ASX was set for another negative day if futures and Wall Street’s drop were any guide — but even with a bad start, Australia’s bourse finished in the green. The ASX 200 fell as much as 0.50% in the first few minutes of trade but closed...

It is developing two proprietary, orally available, small molecule Focal Adhesion Kinase inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases.

The pharmaceutical company plans to initiate patient recruitment at Australian sites in the first quarter of 2022.

Highlights The ASX 200 fell 18.7 points or 0.25% to 7,418.6 in the opening session, while the ASX All ordinaries index was 0.24% down at 7,722.1.   The market breadth is extremely weak so far today, with 10 out of the 11 sectors trad...

The ASX 200 health stocks index (XHJ) has lifted by 0.19% at the time of writing, compared to the broader ASX 200 index which fell by 0.70%. The cancer and fibrosis focused company, Amplia Therapeutics (ASX:ATX), has completed the design fo...

Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) has completed the design for a Phase 2 clinical trial of its focal adhesion kinase (FAK) inhibitor AMP945 for the treatment of advanced pancreatic cancer. The design is based...

Just under two years since Otto Buttula became chairman of Rhythm Biosciences (ASX:RHY), it has gained over 500% since – and the boss of the high flying biotech just chipped more in. Buttula, who in the past has headed financial services fi...

The ASX 200 finished in the red today, as the big end of town played second fiddle to the microcap Emerging Companies index which posted a solid ~0.7% gain. Mining stocks dragged on the broader index, as BHP (ASX:BHP) traded ex-dividend (it...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...